{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.7","upperLimit":"7.5","value":"6.5"},{"groupId":"OG001","lowerLimit":"2.8","upperLimit":"3.7","value":"3.1"},{"groupId":"OG002","lowerLimit":"2.8","upperLimit":"4.6","value":"3.5"},{"comment":"The upper confidence interval was not assessable due to insufficient number of participants with events.","groupId":"OG003","lowerLimit":"2.8","upperLimit":"NA","value":"5.6"},{"groupId":"OG004","lowerLimit":"3.0","upperLimit":"9.1","value":"5.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"25"}],"units":"Participants"}],"description":"A secondary efficacy endpoint is time to PSA progession. Time to PSA progression is defined as the time from first dose of rucaparib to the date that a ≥ 25% increase and absolute increase of ≥ 2 ng/mL above the nadir (or baseline if there was no PSA decline after baseline) in PSA was measured, plus 1 day. The increase must be confirmed by a second consecutive assessment conducted at least 3 weeks later (unless the PSA progression occurred at the last recorded PSA assessment). If confirmed, the date used for time of PSA progression is the earlier of the 2 PSA dates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with a deleterious BRCA (breast cancer susceptibility gene) mutation detected in their tumor.","id":"OG000","title":"BRCA Mutation"},{"description":"Patients with a deleterious ATM (ataxia telangiectasia mutated serine/threonine kinase) mutation detected in their tumor.","id":"OG001","title":"ATM Mutation"},{"description":"Patients with a deleterious CDK12 (Cyclin-dependent kinase 12) mutation detected in their tumor.","id":"OG002","title":"CDK12 Mutation"},{"description":"Patients with a deleterious CHEK2 (Checkpoint Kinase 2) mutation detected in their tumor.","id":"OG003","title":"CHEK2 Mutation"},{"description":"Patients with other deleterious HRR (homologous recombination repair) gene mutation detected in their tumor.","id":"OG004","title":"Other Gene Mutation"}],"paramType":"MEDIAN","populationDescription":"All patients who had a PSA value at baseline.","reportingStatus":"POSTED","timeFrame":"PSA assessments were done at baseline, Week 5, Week 9, every 4 weeks thereafter, and at Treatment Discontinuation. Total follow-up was up to approximately 39 months.","title":"Time to PSA Progression by Gene","type":"SECONDARY","unitOfMeasure":"months"}